MAGEC2 and pancreatic neoplasm: Similarly, for a given cancer type, higher expression of some other CTAs is often correlated with worse outcome, such as MAGE-A3 for pancreatic cancer [59], MAGE-C2 for hepatocellular carcinoma [60], and NY-ESO-1 for malignant melanoma [61].